We develop and operate digital solutions for any chronic condition where improved patient engagement and education can deliver better treatment experiences and outcomes. Our digital therapeutics are adapted to all chronic pathologies for which an increased patient engagement and personalized education can help improve the real-world treatment experience. Leveraging our Theraxium platform , expert teams and robust processes, we can support our life sciences partners across a variety of therapeutics areas.
We are always on the lookout for new collaboration opportunities in oncology, immunology, neurology, rare diseases and beyond. In diabetes, Voluntis designs digital therapeutics to support people with type 1 and type 2 diabetes and their care teams in the management of insulin therapy.
Based on a mobile app for patients and a web application for the care team, our DTx solution provides automated insulin dose recommendations and coaching messages, while enabling the care team to remotely monitor progress. This also enables providers to deliver personalized telemedicine services, a practice increasingly supported by payers worldwide.
Insulia should not be used for premixed insulin. Insulia should not be used in the following populations: pregnant women; non-adult patients; patients that are treated with a basal plus or a basal, bolus regimen i. Please carefully read product instructions and if in doubt, please consult your care team before use. For anticoagulation therapy, adherence is crucial : the INR International Normalized Ratio must be periodically measured to ensure the appropriate dosage of the vitamin K antagonist treatment.
The solution, CoaguChek Link, centralized the INR data measured by patients and connected them with independent diagnostic testing facilities for efficient telemonitoring. Key outcomes were the simplification of care delivery, improvement of adherence and strengthening of care teams and patients relationship for enhanced anticoagulation therapy management.
